n(4)-hexadecyl-1-arabinofuranosylcytosine has been researched along with Leukemia in 1 studies
*Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horber, DH; Schott, H; Schwendener, RA | 1 |
1 other study(ies) available for n(4)-hexadecyl-1-arabinofuranosylcytosine and Leukemia
| Article | Year |
|---|---|
Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Cell Differentiation; Cytarabine; Dipyridamole; DNA; Drug Carriers; Drug Interactions; Half-Life; Humans; Leukemia; Liposomes; Tumor Cells, Cultured | 1995 |